Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of tinengotinib combined with novel endocrine therapy in previously treated metastatic castration-resistant prostate cancer
CTR20262772Phase 2Active
- Sponsor
- TransThera Biosciences
- Start
- Jul 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tinengotinib, darolutamide, enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by TransThera Biosciences. Started Jul 2026; status: active.
02
Drugs
tinengotinibdarolutamideenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20262772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262772.